Genentech

Aggressive lobbying keeps seniors on Lucentis, prevents Medicare savings, USA TODAY article states

By

Lobbying efforts have ensured that long-term care residents and other seniors are commonly prescribed the expensive drug Lucentis, even though the less costly drug Avastin has proven equally effective, suggests a USA TODAY article published Thursday. Lucentis in fact has become the No. 1 drug reimbursed by Medicare.

Protective gene mutation gives hope to Alzheimer's drug development

By

Alzheimer's researchers got a huge boost last week with the publication of a study showing that a rare genetic mutation prevents the buildup of beta amyloid in the brain.

Avastin more likely to cause blindness than Lucentis, study reports

By

The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.

Group recommends coordinating care for dual-eligibles, leaving more up to states

In order to promote coordination between Medicare and Medicaid services and to save money, the federal government and states should create an integrated care model for dual-eligible beneficiaries, a new report recommends.

FDA approves new macular degeneration treatment

The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.

Macular degeneration treatment linked to blindness, FDA advisory says

Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.

Don't miss any McKnight's news

Featured Articles